Vital capacity – Talk Bio

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

2 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

2 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

2 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

2 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

Zaka VC Invests in DeepSeq.AI to Transform AI-Based Protein Drug Discovery

3 weeks ago talkbio0Tagged AI-based drug discovery, DARPA-funded initiative * *, datasets, DeepSeq, hyperscaled data, Illumina Ventures, Investments, LLM-based technology, prepulse inhibition activity, protein drug discovery, Vital capacity, Zaka

Zaka VC; DeepSeq.AI; protein drug discovery; AI-based drug discovery; hyperscaled data; LLM-based technology; biotech investment; DARPA-funded initiative; Illumina Ventures; PPI datasets

Health tech investors are getting creative with exits in 2025

2 months ago talkbio0Tagged 2025, AI healthtech IPOs, Exit, healthtech, Investments, M&A consolidation, Private Equity, provider operations, roll-ups, secondary markets, trends qualifier, Vital capacity

healthtech exits 2025; creative exit strategies; M&A consolidation; secondary markets; private equity roll-ups; AI healthtech IPOs; provider operations investment; VC healthtech trends

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

12 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

PureTech’s Deupirfenidone Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Patients

1 year ago talkbio0Tagged decline, Force, High, Idiopathic Pulmonary Fibrosis, IPF, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology, Vital capacity, Vital capacity test

Deupirfenidone, Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Forced Vital Capacity (FVC), ELEVATE IPF Phase 2b Trial, PureTech Health